{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"6"}]}],"title":"Overall Response rate (CR+PR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"29"}],"units":"Participants"}],"description":"BOR is defined as a complete response or partial response assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. Partial response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.","groups":[{"description":"Participants with Human Papillomavirus Associated Malignancies (N = 50, 47 from Cohort 1, 3 from Cohort 2)","id":"OG000","title":"All Participants"},{"description":"Participants with Human Papillomavirus 16 Tumors (HPV16+) from both Cohort 1 and Cohort 2 further stratified by prior immune checkpoint blockade.\n\n(N=37; 34 from Cohort 1, 3 from Cohort 2)","id":"OG001","title":"Participants With Human Papillomavirus 16 (HPV16+) Tumors"},{"description":"Participants with tumor testing positive for HPV16 and no previous exposure to an immune checkpoint blockade agent.\n\n(N= 8; 7 from Cohort 1, 1 from Cohort 2)","id":"OG002","title":"Human Papillomavirus 16 Tumors (HPV-16+), Immune Checkpoint Blockade (ICB) - Naive"},{"description":"Participants with tumor testing positive for HPV16 and disease progression following prior treatment with immune checkpoint blockade agent.\n\n(N= 29; 27 from Cohort 1, 2 from Cohort 2)","id":"OG003","title":"Human Papillomavirus 16 Tumors (HPV-16+), Immune Checkpoint Blockade (ICB) - Resistant"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"48 participants were screened for Cohort (C)1, 1 was a screen fail =\\> 47 were treated on C1. 3 participants were screened for C2 and were treated on it. 50 participants (47 in C1 and 3 in C2) comprise the complete treated population (\"All participants\"). As pre-specified by the protocol cohort 2 is not required to be reported independently.","reportingStatus":"POSTED","timeFrame":"Every 2 months, up to approximately 10 months","title":"Best Overall Response (BOR) in Checkpoint Naive and Immune Checkpoint Blockade (ICB) Resistant Disease in Participants With Advanced or Metastatic Human Papillomavirus (HPV) Associated Malignancies","type":"PRIMARY","unitOfMeasure":"Participants"}